Keiichiro Mukai

Dr. Keiichiro Mukai


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
HMHisato Matsunaga
Hisato Matsunaga
KMKeiichiro Mukai
Keiichiro Mukai
KYKyosuke Yamanishi
Kyosuke Yamanishi

12 July 2023 in Comprehensive Psychiatry
Verified
Journal Article
Open access
MMMasahiro Miyauchi
Masahiro Miyauchi
NMNaomi Matsuura
Naomi Matsuura
KMKeiichiro Mukai
Keiichiro Mukai
THTakuya Hashimoto
Takuya Hashimoto
SOShun Ogino
Shun Ogino
HMHisato Matsunaga
Hisato Matsunaga
A close association between obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) in children and adolescents has been investigated in previous studies. However, few studies examined the relationship between lifetime comorbidity of ADHD and OCD in adults. Therefore, we sought to investigate the clinical and psychopathological features related to comorbid ADHD in Japanese adult patients with OCD. We assessed lifetime comorbidity of ADHD in 93 adult Japanese patients with OCD. Additionally, we used the Japanese version of Conners' Adult ADHD Rating Scales to assess the characteristics and severity of ADHD in each participant. According to the results, we excluded OCD patients that did not have ADHD but who exhibited elevated levels of ADHD traits. We compared OCD patients with ADHD (ADHD+ group) and those without ADHD or its trait (ADHD- group) in terms of background profiles and clinical features, such as OCD symptomatology and psychometric test results. Additionally, the 6-month treatment outcome was compared prospectively between groups. Of the 93 OCD participants, the prevalence of lifetime comorbidity of ADHD was estimated as 16.1%. Compared with the ADHD- group, participants in the ADHD+ group had an earlier age of onset of OCD, higher frequencies of hoarding symptoms, higher levels of depressive and anxiety symptoms and lower quality of life, more elevated levels of impulsivity, and higher rates of substance or behavioral addiction and major depression. Finally, the mean improvement rate on the Yale-Brown Obsessive Compulsive Scale after 6 months of standardized OCD treatment in the ADHD+ group (16.1%) was significantly lower than that in the ADHD- group (44.6%). The lifetime comorbidity of ADHD is likely to exert a significant effect on clinical features and treatment outcome in adult patients with OCD. It is important to consider that underlying ADHD pathology may function as a facilitator for increased severity of global clinical features and treatment refractory conditions in OCD patients. Further studies are required to examine treatment strategies for such patients.

25 November 2019 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
Kyosuke YamanishiKyosuke Yamanishi
Kyosuke Yamanishi
THTakuya Hashimoto
Takuya Hashimoto
MMMasahiro Miyauchi
Masahiro Miyauchi
KMKeiichiro Mukai
Keiichiro Mukai
KIKaoru Ikubo
Kaoru Ikubo
HMHisato Matsunaga
Hisato Matsunaga
Interleukin (IL)‑18 is an interferon γ‑inducing inflammatory cytokine associated with function of the immune system and other physiological functions. IL‑18‑deficient (Il18‑/‑) mice exhibit obesity, dyslipidemia, non‑alcoholic steatohepatitis and depressive‑like behavioral changes. Therefore, IL‑18 has a number of important roles associated with immunity, energy homeostasis and psychiatric conditions. In the present study, gene expression in the brains of Il18‑/‑ mice was analyzed to identify genes associated with the depressive‑like behaviors and other impairments displayed by Il18‑/‑ mice. Using whole genome microarray analysis, gene expression patterns in the brains of Il18+/+ and Il18‑/‑ mice at 6 and 12 weeks of age were examined and compared. Subsequently, genes were categorized using Ingenuity® Pathway Analysis (IPA). At 12 weeks of age, 2,805 genes were identified using microarray analysis. Genes related to ‘Major depression’ and ‘Depressive disorders’ were identified by IPA core analysis, and 13 genes associated with depression were isolated. Among these genes, fibroblast growth factor receptor 1 (Fgfr1); protein tyrosine phosphatase, non‑receptor type 1 (Ptpn1); and urocortin 3 (Ucn3) were classed as depression‑inducing and the other genes were considered depression‑suppressing genes. Subsequently, the interactions between the microarray results at 6 weeks of age and the above three depression‑inducing genes were analyzed to search for effector genes of depression at 12 weeks of age. This analysis identified cyclin D1 (Ccnd1) and NADPH oxidase 4 (Nox4). The microarray analysis results were correlated with the results of reverse transcription-quantitative PCR (RT-qPCR). Overall, the results suggest that Fgfr1, Ptpn1 and Ucn3 may be involved in depression‑like changes and Ccnd1 and Nox4 regulate these three genes in IL‑18‑deficient mice.

5 February 2021 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
KMKeiichiro Mukai
Keiichiro Mukai
NMNaomi Matsuura
Naomi Matsuura
MMMasahiro Miyauchi
Masahiro Miyauchi
THTakuya Hashimoto
Takuya Hashimoto
Kyosuke YamanishiKyosuke Yamanishi
Kyosuke Yamanishi
HMHisato Matsunaga
Hisato Matsunaga
Aim A tic‐related specifier is included in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM‐5) diagnostic criteria to identify a clinically‐specific obsessive compulsive disorder (OCD) subtype. The current study sought to evaluate hemodynamic changes during executive function tasks among OCD patients with and without a lifetime history of tic disorder (TD) and healthy controls, and to investigate the relationship between brain activation and clinical variables in each group using structured equation modeling. Methods Twenty‐nine OCD patients diagnosed according to DSM‐IV‐TR and 15 healthy controls were recruited. Patients were divided into two groups by the presence or absence of a lifetime history of TD (TD+; 11, TD−; 18). Prefrontal hemodynamic changes were measured using multi‐channel near‐infrared spectroscopy during the verbal fluency task, trail making task, and Tower of London (ToL) task. Results There were significant brain activation differences in frontopolar cortex between OCD patients with and without TD during verbal fluency task and ToL performance. Brain activation in dorsolateral prefrontal cortex (DLPFC) during the ToL task in OCD patients with TD exerted a direct causal effect on the severity of compulsions. In addition, we detected a direct causal effect of the severity of obsessions in OCD patients without TD on brain activation in DLPFC during the ToL task. Conclusion Brain activation in frontopolar cortex exhibits different hemodynamics depending on the task, and DLPFC function may play a different role in the neural basis of developing OCD symptoms between OCD patients with and without TD.

7 March 2018 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Kyosuke YamanishiKyosuke Yamanishi
Kyosuke Yamanishi
KMKeiichiro Mukai
Keiichiro Mukai
THTakuya Hashimoto
Takuya Hashimoto
KIKaoru Ikubo
Kaoru Ikubo
KNKeiji Nakasho
Keiji Nakasho
HMHisato Matsunaga
Hisato Matsunaga
Background: The cytokine interleukin-18 was originally identified as an interferon-gamma-inducing proinflammatory factor; however, there is increasing evidence to suggest that it has non-immunological effects on physiological functions. We previously investigated the potential pathophysiological relationship between interleukin-18 and dyslipidemia, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, and suggested interleukin-18 as a possible novel treatment for not only these diseases but also for cancer immunotherapy. Before clinical application, the effects of interleukin-18 on the kidney need to be determined. In the current study, we examined the kidney of interleukin-18 knockout (Il18(-/-)) mice and the effects of interleukin-18 on the kidney following intravenous administration of recombinant interleukin-18. Methods: Il18(-/-) male mice were generated on the C57Bl/6 background and littermate C57Bl/6 Il18(+/+) male mice were used as controls. To assess kidney damage, serum creatinine and blood urea nitrogen levels were measured and histopathological analysis was performed. For molecular analysis, microarray and quantitative reverse transcription PCR was performed using mice 6 and 12 weeks old. To evaluate the short-and long-term effects of interleukin-18 on the kidney, recombinant interleukin-18 was administered for 2 and 12 weeks, respectively. Results: Compared with Il18(+/+) mice, Il18(-/-) mice developed kidney failure in their youth-6 weeks of age, but the condition was observed to improve as the mice aged, even though dyslipidemia, arteriosclerosis, and higher insulin resistance occurred. Analyses of potential molecular mechanisms involved in the onset of early kidney failure in Il18(-/-) mice identified a number of associated genes, such as Itgam, Nov, and Ppard. Intravenous administration of recombinant interleukin-18 over both the short and long term showed no effects on the kidney despite significant improvement in metabolic diseases. Conclusions: Short- and long-term administration of interleukin-18 appeared to have no adverse effects on the kidney in these mice, suggesting that administration may be a safe and novel treatment for metabolic diseases and cancer.

28 July 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
KMKeiichiro Mukai
Keiichiro Mukai
YKYamanishi Kyosuke
Yamanishi Kyosuke
SOShun Ogino
Shun Ogino
YHYukihiko Hosoi
Yukihiko Hosoi
KHKazuhisa Hayashida
Kazuhisa Hayashida
HMHisato Matsunaga
Hisato Matsunaga
There is a growing need for widely available, cost-effective, and low-intensity treatments for OCD. Although cognitive–behavioral therapy (CBT) is often the first line of treatment, barriers to providing CBT in OCD patients remain unresolved. In this narrative review, we summarize the current literature on the benefits and challenges of using CBT to treat OCD, review the potential of low-intensity, technology-based CBT programs, and identify issues related to the use of these new approaches. We identified articles to include in this narrative review by entering the following search terms into PubMed, PsychInfo, Web of Science, and Google Scholar: obsessive–compulsive disorder, OCD, cognitive–behavioral therapy, CBT, technolog*, digital. The final literature search was conducted on 13 July 2024, and after checking 68 potentially relevant studies according to our inclusion and exclusion criteria, we included 24 studies (14 review articles and 10 original articles) in the present review. We identified several main factors associated with the accessibility and effectiveness of CBT. Incentives for healthcare practitioners who undergo CBT training may increase the availability of this treatment option. Furthermore, treatment efficacy is related to patient treatment adherence, which may be enhanced by offering low-intensity and convenient treatment options such as digital CBT programs. These findings highlight both the potential and the current limitations of low-intensity and digital CBT approaches for OCD treatment. Although low-intensity and technology-based CBT programs can serve as relatively convenient, effective, and accessible treatment options, further research is needed to examine patient perceptions, and determine the most important characteristics of such programs for optimal treatment efficacy.